What is currently known about the potential effect of vitamin D (VitD) on modulating some hallmarks of aging.
Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of final data from the RESTORE open-label/switch study, demonstrating